Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Treatment of metastatic melanoma: an overview Bhatia S; Tykodi SS; Thompson JAOncology (Williston Park) 2009[May]; 23 (6): 488-96The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy is the mainstay of treatment for most patients. Single-agent chemotherapy is well tolerated but is associated with response rates of only 5% to 20%. Combination chemotherapy and biochemotherapy may improve objective response rates but do not extend survival and are associated with greater toxicity. Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients. In this article, we review the treatments for metastatic melanoma including promising investigational approaches.|Adoptive Transfer[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antigens, CD/immunology[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH]|Cancer Vaccines[MESH]|Humans[MESH]|Immunotherapy[MESH]|Interferon alpha-2[MESH]|Interferon-alpha/therapeutic use[MESH]|Interleukin-2/therapeutic use[MESH]|Ipilimumab[MESH]|Melanoma/mortality/pathology/*therapy[MESH]|Prognosis[MESH]|Recombinant Proteins[MESH]|Skin Neoplasms/mortality/pathology/*therapy[MESH] |